Neurogene (NGNE) Other financing activities (2014 - 2026)
Neurogene's (NGNE) quarterly Other financing activities came in at $201000.0 in Q1 2026, up 957.89% YoY from $19000.0 in Q1 2025, and up 331.03% on a QoQ basis from -$87000.0 in Q3 2025.
Neurogene (NGNE) Other financing activities (2014 - 2026) Analysis & Trends
Neurogene (NGNE) has 13 years of Other financing activities data on file, last reported at $201000.0 in Q1 2026.
- Quarterly Other financing activities rose 957.89% year-over-year to $201000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $182000.0 (down 95.05% YoY) and the FY2024 annual result came in at $4.3 million, changed N/A from the prior year.
- Other financing activities grew to $201000.0 in Q1 2026, from -$87000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $3.2 million in Q3 2024 to a low of -$2.0 million in Q4 2023.
- A 5-year average of $304066.7 and a median of $71000.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 2476.06% in 2023, down 3114.75% in 2023.
- Tracing NGNE's Other financing activities over 5 years: stood at -$61000.0 in 2022, then sank by 3114.75% to -$2.0 million in 2023, then jumped by 265.37% to $3.2 million in 2024, then plunged by 102.68% to -$87000.0 in 2025, then jumped by 331.03% to $201000.0 in 2026.
- The last three Other financing activities figures came in at $201000.0 (Q1 2026), -$87000.0 (Q3 2025), and $68000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22,000.00 |
| Jun 30, 2026 | 22,000.00 |
| Mar 31, 2026 | 201,000.00 |
| Mar 31, 2026 | 201,000.00 |
| Sep 30, 2025 | -87,000.00 |
| Sep 30, 2025 | -87,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Sep 30, 2024 | 3.24 Mn |
| Sep 30, 2024 | 3.24 Mn |
| Jun 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 415,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Dec 31, 2023 | -1.96 Mn |
| Dec 31, 2023 | -1.96 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Sep 30, 2023 | 1.83 Mn |